Exact Sciences Corporation (EXAS)
Automate Your Wheel Strategy on EXAS
With Tiblio's Option Bot, you can configure your own wheel strategy including EXAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXAS
- Rev/Share 15.1388
- Book/Share 12.8305
- PB 4.4909
- Debt/Equity 1.0519
- CurrentRatio 2.7272
- ROIC -0.1967
- MktCap 10869321560.0
- FreeCF/Share 1.0392
- PFCF 55.9865
- PE -10.5547
- Debt/Assets 0.4415
- DivYield 0
- ROE -0.3642
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EXAS | Mizuho | -- | Outperform | -- | $60 | April 10, 2025 |
| Initiation | EXAS | RBC Capital Mkts | -- | Sector Perform | -- | $52 | March 13, 2025 |
| Initiation | EXAS | Barclays | -- | Overweight | -- | $70 | Jan. 23, 2025 |
| Initiation | EXAS | Wells Fargo | -- | Overweight | -- | $75 | Aug. 28, 2024 |
News
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard®.
Read More
Exact Sciences Earns 2025 Great Place To Work® Certification™
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and le.
Read More
Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Positive
Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue decline, the market response was positive due to promising growth projections and the launch of Cologuard Plus, a next-gen colon cancer screening test. Competition and high market cap valuation pose challenges, but Exact's first-mover advantage and new product launches offer potential for continued revenue growth.
Read More
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance
Published: May 02, 2025 by: Benzinga
Sentiment: Positive
Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
3 Top Cancer Biotechs to Keep An Eye On in 2025
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Read More
2 Stocks Down 59% and 34% to Buy and Hold
Published: February 24, 2025 by: The Motley Fool
Sentiment: Positive
Warren Buffett, arguably the greatest investor of all time, once said it is wise for investors to be fearful when others are greedy. One way to apply this advice from the Oracle of Omaha is to look at a soaring stock market and identify companies that aren't performing nearly as well -- or are just performing poorly -- but still have attractive prospects.
Read More
Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Positive
Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core business shows momentum, with strong demand for Cologuard and a solid cash position of $1.04B. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.
Read More
Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Catherine Schulte - Baird Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Jack Meehan - Nephron Research Andrew Brackmann - William Blair Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Subu Nambi - Guggenheim Securities Puneet Souda - Leerink …
Read More
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Exact Sciences (EXAS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.27 per share a year ago.
Read More
About Exact Sciences Corporation (EXAS)
- IPO Date 2001-02-01
- Website https://www.exactsciences.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Kevin T. Conroy J.D.
- Employees 6900